ACADIA Pharmaceuticals Has This Top Analyst Even More Positive on PDP Drug Nuplazid’s Opportunity

ACADIA Pharmaceuticals (NASDAQ:ACAD) just yielded a third quarter outclass that has one of the Street’s top analysts impressed in the upshot. What commercial success does Cowen analyst Ritu Baral spot ahead for the biotech player’s Parkinson’s disease psychosis asset Nuplazid?

Story Continues